From Snapshots to Movies
The Emergence of 3D Printing in Expanding Clinical Research and Pharmaceutical Compounding
Complex Journey from Innovation to Patient impact
Electronic Logs - The next phase of execution maturity in pharma
LYMPHOMA TREATMENT AT A CROSSROADS
EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
Designing and Developing Green Drug Delivery Systems: From natural bioactives to sustainable therapeutics
Associate Professor, Somaiya Institute for Research and Consultancy
Dr Maushmi S Kumar is a Life Sciences Researcher Academician and Translational Drug Discovery Scientist with years of experience across academia and pharmaceutical industry Her research spans drug design marine bioactives chemical biology molecular pharmacology and advanced drug delivery with a strong focus on translating discoveries toward therapeutic development for cancer and neurodegenerative...
Articles
Biologics at Scale
Biologics including monoclonal antibodies vaccines and advanced cell and gene therapies CGT require an integrated innovation and production ecosystem This ecosystem rests on six pillars Manufacturing Infrastructure Regulatory Environment Talent and Training Innovation Hubs Funding s Investment and PublicPrivate Partnerships In recent years global and AsiaPacific leaders have accelerated efforts...
Research Insights
Dynamic Conformational Change Regulates the Protein-DNA Recognition: An Investigation on Binding of a Y-Family Polymerase to Its Target DNA
Abstract ProteinDNA recognition is a central biological process that governs the life of cells A protein will often undergo a conformational transition to form the functional complex with its target DNA The protein conformational dynamics are expected to contribute to the stability and specificity of DNA recognition and therefore may control the functional
Case Studies
High Concentration Antibody - Rituximab
Challenge Antibodies tend to aggregate at the high concentrations typically required for their therapeutic application The key challenge of this study was to reduce the rate of aggregation in isotonic aqueous formulation of rituximab at mgml whilst maintai
Techno Trends
China's New Drug Approval Regulations Aim to Expedite Market Entry for Biologics
New regulations in China are designed to accelerate the approval process for biologics
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Use of Steroids in COVID-19 patients
Anoop Kumar currently working as Assistant Professor in Department of Pharmacology and Clinical Research, Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi, India. He has authored more than 70 research and review articles and 10 book chapters in International Journal of repute. His research interests are Drug repurposing, Meta-analysis, Risk and benefit analysis of drugs and Pharmacoeconomic studies.
From Gene Editing to Network Medicine
Prof. Dr. Hemanth Kumar Manikyam is a researcher in natural products chemistry and systems pharmacology. He is widely known as the father of Intrinsic Network Pharmacology (INP), an integrative framework combining artificial intelligence, biological network analysis, and traditional medicinal knowledge to explore complex therapeutic mechanisms and next-generation precision medicine.
The Therapeutics Landscape of Miniproteins
Victor H. Bustos, Ph.D., is the Vice President of Preclinical R&D at Ordaos Bio. A specialist in protein engineering with a doctorate in Biomedicine, he leads the design of AI-generated mini-proteins. Previously, he spent 17 years at Rockefeller University focusing on complex cellular mechanisms and therapeutic target validation.
Alena Romanova is a Scientist I at Ordaos Bio, where she develops experimental workflows for protein characterisation and biologics discovery, including the application of cell-free protein expression and biochemical assays.
Precision medicine for Alzheimer’s Disease
Dr Parmi is a scientific researcher and an expert medical writer with Ph.D specialising in neurosciences. With an extensive pharmaceutical and healthcare industry experience, she excels at driving innovation. Focused at patient’s centricity, she has played key role in developing innovative medicines that makes meaningful impact on patient’s lives. Dr Parmi has made significant contribution at establishing a patented mouth-dissolving strip (MDS) manufacturing facility. With proven expertise in novel product development, her strong emphasis on quality manufacturing has led to structuring of quality documentation practices for this novel & patented MDS technology aligned with regulatory standards.
Dr Parmi has made significant contributions in field of neuroscience research with multiple acclaimed publications. A distinguished medical writer, she serves as editorial board member and peer reviewer in prestigious journals and continuous to make an impact in her field. Author at reputed public health platform, she writes to promote health awareness. Recognised for her exceptional contributions, she is a multiple-time government R&D grant recipient, particularly in neurodegenerative disorder studies.
Kinase Inhibitors as Antiviral Agents
Thanigaimalai Pillaiyar is working as an independent junior research group leader and establishing a research group at the Tübingen Center for Academic Drug Discovery (TüCAD2), University of Tübingen. His research interests include medicinal chemistry of orphan G protein-coupled receptors (GPCRs), synthetic organic chemistry, and dual SARS-CoV-2 Mpro-kinase inhibitors.
Stefan Laufer is Professor for Pharmaceutical/Medicinal Chemistry at Tuebingen University and chairs the TüCAD2. His research interests are anti inflammatory and cancer drug discovery. He authored more than 500 publications, 15 books/book chapters and is inventor in 42 patent families with >330 national applications. 4 compounds from his lab made it to first into man studies.
press releasesRead more...
ProBio Enters Exclusive Global Licensing Agreement with AbTis to Develop Next-Generation ADC Asset
ProBio a global contract research development and manufacturing organization CRDMO today announced that it has entered into an exclusive global licensing agreement with AbTis Co Ltd
AGC Biologics partners with Child’s Cure Genetic Research to pursue mRNA-based therapeutic for severe epileptic disorder
In a world where patients with CDKL deficiencies can suffer to epileptic seizures a day a contract biopharmaceutical manufacturer and a parentfounded foundation will partner on earlystage
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery
Rakovina Therapeutics Inc TSXV RKV FSE JO OTCMKTS RKVTF a biopharmaceutical company advancing innovative cancer therapies through AIpowered drug discovery today announced
Roche opens up new possibilities for genomic research in Asia Pacific with next-generation sequencing technology
Roche is advancing its nextgeneration sequencing NGS ambitions in Asia Pacific following the global launch of AXELIOS in June Building on early adoption in South Korea Roche will bring the transformative technology closer to researchers and laboratory leaders across the region through AXELIOS Days
Charles River Laboratories to Acquire Frontage’s Bioanalysis and DMPK Businesses
Charles River Laboratories International Inc announced today that it has entered into definitive agreements to acquire Frontage Holdings Corporations bioanalysis and DMPK operations in Exton Pennsylvania for approximately million in cash subject to customary closing adjustments In addition to the i...
Sino Biological Advances AI-Designed Molecule Validation with 4RISE™
AI can generate protein candidates at an unprecedented speed but experimental validation remains essential to determine whether they properly express bind targets and demonstrate the desired biological properties Sino Biological Inc Shenzhen Stock Exchange SZ a global leader in recombinant protein t...
EventsRead more...
09 - 11
Nov 202611th Microbiome Movement USA Summit
The Colonnade Hotel, Boston, M...
10 - 11
Nov 2026Extractables & Leachables Europe
Parkhotel Schӧnbrunn, Vienna,...
11 - 13
Nov 2026Frontiers in Cancer Science 2026
One Farrer Hotel,1 Farrer Park...
11 - 12
Nov 2026Medical Device Project and Portfolio Management
Chicago, IL, USA
16 - 17
Nov 2026Analytics for Smarter Decisions in Pharma
London, UK
24 - 27
Nov 2026Pharmtech & Ingredients 2026
Crocus Expo, Pavilion 2, Mosco...
24 - 25
Nov 2026BioPharma Deals Conference 2026
Science Congress Center, Munic...
26 - 28
Nov 2026One Health Conference 2026
Thapar Institute of Engineerin...
LATEST NEWSRead more...
Shionogi Enters into Licence Agreement with Link for Antibiotic Cefiderocol
Shionogi has entered into a licence agreement with Link Healthcare Singapore to develop and commercialise cefiderocol in Singapore and Malaysia
IDEL Therapeutics Partners with Daiichi Sankyo to Develop Multi-Drug Conjugates for Solid Tumours
IDEL Therapeutics has entered into a global research collaboration with Daiichi Sankyo to evaluate a multidrug conjugate MDC using iDELs synthetic shuttle platform for the treatment of selected solid tumours The multiyear collaboration will focus on the preclinical evaluation of a new class of MDCs...
Bayer’s Asundexian Receives Approval for Secondary Stroke Prevention
Bayer has received approval from the US Food and Drug Administration FDA for asundexian mg tablets marketed under the brand name Sunharbo to reduce the risk of recurrent stroke in adults following a recent noncardioembolic ischaemic stroke or highrisk transient ischaemic attack TIA
Johnson & Johnson Receives Approval for RYBREVANT FASPRO to Treat Advanced Head and Neck Cancer
Johnson Johnson has received accelerated approval from the US Food and Drug Administration FDA for RYBREVANT FASPRO amivantamab and hyaluronidaselpuj to treat adults with recurrent or metastatic head and neck squamous cell carcinoma HNSCC
Boehringer Ingelheim Enters into Partnership with SBP Group to Advance Next-Generation Cancer Therapies
Boehringer Ingelheim and Sino Biopharmaceutical SBP Group have entered into a multiprogram partnership to develop potential nextgeneration cancer treatments using antibodydrug conjugate ADC and Tcell engager TcE technologies
MindWalk Partners with Teva to Support Antibody Discovery Using AI
MindWalk has entered into a multiyear agreement with Teva Pharmaceuticals Australia to support antibody discovery and design optimisation using AI technology ReefIQ is MindWalks biological context platform for the life sciences sector powered by its HYFT technology The technology
